Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $200M Series A (Mar 2026) at $2B+ valuation led by AON Consulting. 91%+ medication adherence. GLP-1 benefits platform for employers. Linda Yaccarino CEO.
eMed is a GLP-1 and metabolic health benefits platform built specifically for employer-sponsored health plans, the fastest-growing category in US workplace benefits. The company raised $200 million in Series A financing in March 2026 at a $2 billion+ valuation led by AON Consulting, with backing from Linda Yaccarino (former Twitter/X CEO, now eMed CEO) and Tom Brady. Claiming 91%+ medication adherence rates, eMed positions itself as the most effective GLP-1 benefits program available to employers.
Benchling is a life sciences R&D cloud platform with ~$200M+ ARR. Series E startup valued at ~$6.1B. Trusted by Pfizer, Genentech, and 1,000+ biotech/pharma teams. HQ: San Francisco.
Benchling is a cloud-based research and development platform purpose-built for the life sciences industry, founded in 2012 by Sajith Wickramasekara and Ashu Singhal as a Y Combinator alumnus. The company offers an integrated suite of tools including electronic lab notebooks (ELN), laboratory information management systems (LIMS), molecular biology design tools, and data management platforms, all connected in a unified cloud environment.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.